LC
KYNB

Lindbrook Capital’s Kyntra Bio KYNB Stock Holding History

Lindbrook Capital’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2
Closed -$105 – 2729
2023
Q2 		$105 Sell
2
-21
-91% -$8.69K ﹤0.01% 2663
2023
Q1 		$10.7K Sell
23
-6
-21% -$3.17K ﹤0.01% 1412
2022
Q4 		$11.6K Buy
29
+21
+263% +$8.04K ﹤0.01% 1366
2022
Q3 		$3K Buy
8
+1
+14% +$322 ﹤0.01% 1866
2022
Q2 		$2K Buy
+7
New +$1.79K ﹤0.01% 1953
2021
Q2 		– Sell
-20
Closed -$17K – 1938
2021
Q1 		$17K Buy
+20
New +$21.3K ﹤0.01% 806
2020
Q1 		– Sell
-20
Closed -$21K – 1732
2019
Q4 		$21K Buy
+20
New +$20.4K 0.01% 722
2019
Q2 		– Sell
-20
Closed -$27K – 1434
2019
Q1 		$27K Buy
20
+12
+150% +$16.3K 0.01% 597
2018
Q4 		$9K Buy
+8
New +$8.99K ﹤0.01% 845

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lindbrook Capital's KYNB Position: Q3 2023 in Review

Lindbrook Capital sold out of Kyntra Bio (KYNB) in Q3 2023, closing a stake of 2 shares — an estimated $105 sold.

Lindbrook Capital first reported a position in KYNB in Q4 2018 and held it in 9 quarters. The position peaked at $27K in Q1 2019. 110 funds tracked by Wall St. Rank hold KYNB as of Q3 2023.

  • Lindbrook Capital reported no remaining Kyntra Bio position as of Q3 2023 after selling out during the quarter.
  • Lindbrook Capital sold 2 Kyntra Bio shares in Q3 2023, an estimated $105.
  • Lindbrook Capital first reported a position in Kyntra Bio in Q4 2018 and held it in 9 quarters.
  • Lindbrook Capital's Kyntra Bio position peaked at $27K in Q1 2019.
  • 110 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2023.

Based on Lindbrook Capital's 13F filing for Q3 2023, filed 25 Oct 2023.